Pharmacotherapy for Pulmonary Hypertension

被引：16

作者：

Steinhorn, Robin H. ^{[1
]}

机构：

[1] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2012年 / 59卷 / 05期

关键词：

Pulmonary hypertension; Pulmonary vasculature; Vasodilator; Nitric oxide; Phosphodiesterase; Prostacyclin; Endothelin; INHALED NITRIC-OXIDE; ENDOTHELIN RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED-TRIAL; CONGENITAL HEART-SURGERY; TERM NEWBORN-INFANTS; ARTERIAL-HYPERTENSION; INTRAVENOUS EPOPROSTENOL; PRETERM INFANTS; DOUBLE-BLIND; BRONCHOPULMONARY DYSPLASIA;

D O I：

10.1016/j.pcl.2012.07.011

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.

引用

页码：1129 / +

页数：19

共 123 条

[11] Inhaled nitric oxide and related therapies
Barr, Frederick E.
Macrae, Duncan
[J]. PEDIATRIC CRITICAL CARE MEDICINE, 2010, 11 : S30 - S36
[12] Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
Barst, RJ
Ivy, D
Dingemanse, J
Widlitz, A
Schmitt, K
Doran, A
Bingaman, D
Nguyen, N
Gaitonde, M
van Giersbergen, PLM
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) : 372 - 382
[13] Vasodilator therapy for primary pulmonary hypertension in children
Barst, RJ
Maislin, G
Fishman, AP
[J]. CIRCULATION, 1999, 99 (09) : 1197 - 1208
[14] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
Barst, RJ
Rubin, LJ
Long, WA
McGoon, MD
Rich, S
Badesch, DB
Groves, BM
Tapson, VF
Bourge, RC
Brundage, BH
Koerner, SK
Langleben, D
Keller, CA
Murali, S
Uretsky, BF
Clayton, LM
Jobsis, MM
Blackburn, SD
Shortino, D
Crow, JW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
[15] SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN
BARST, RJ
RUBIN, LJ
MCGOON, MD
CALDWELL, EJ
LONG, WA
LEVY, PS
[J]. ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) : 409 - 415
[16] A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
Barst, Robyn J.
Ivy, D. Dunbar
Gaitan, Guillermo
Szatmari, Andras
Rudzinski, Andrzej
Garcia, Alberto E.
Sastry, B. K. S.
Pulido, Tomas
Layton, Gary R.
Serdarevic-Pehar, Marjana
Wessel, David L.
[J]. CIRCULATION, 2012, 125 (02) : 324 - 334
[17] Neonatal persistent pulmonary hypertension treated with milrinone: Four case reports
Bassler, D
Choong, K
McNamara, P
Kirpalani, H
[J]. BIOLOGY OF THE NEONATE, 2006, 89 (01): : 1 - 5
[18] Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: Results from the European postmarketing surveillance program
Beghetti, Maurice
Hoeper, Marius M.
Kiely, David G.
Carlsen, Joern
Schwierin, Barbara
Segal, Eleanor S.
Humbert, Marc
[J]. PEDIATRIC RESEARCH, 2008, 64 (02) : 200 - 204
[19] AEROSOLIZED PROSTACYCLIN FOR PULMONARY-HYPERTENSION IN NEONATES
BINDL, L
FAHNENSTICH, H
PEUKERT, U
[J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1994, 71 (03): : F214 - F216
[20] Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension
Black, SM
Heidersbach, RS
McMullan, DM
Bekker, JM
Johengen, MJ
Fineman, JR
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 277 (05): : H1849 - H1856

← 1 2 3 4 5 6 7 8 9 10 →